
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular Inc demonstrated a robust financial performance with a gross margin expansion of 110 basis points year-over-year to 70%, driven by higher average selling prices and improved manufacturing efficiencies. The company reported a 15% increase in revenue, alongside a 12% rise in operating income to $16.1 million, resulting in a strong operating margin of 25%. Additionally, net income rose by 17% to $13.8 million, supporting a favorable outlook for continued sales growth and enhanced profitability with expectations of a gross margin of 69.7% for the year.
Bears say
LeMaitre Vascular Inc. anticipates a slight decline in its full-year operating margin, projected at 24%, reflecting typical seasonality effects and suggesting potential challenges in maintaining profitability. The company's reduced target for sales representatives, now set at 165, indicates a possible constraint on future growth and sales performance, diverging from previous projections. Furthermore, a significant decrease in R&D expenditure to 6% of revenue, attributed to the culmination of regulatory compliance projects, raises concerns about the firm's commitment to product innovation and its capacity to address competitive pressures and market demand effectively.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares